Close
  Indian J Med Microbiol
 

Figure 2: (a) Percentage of patients with EBV DNA in blood in different groups.aP, 0.09, glucocorticoids versus ASA;bP, 0.008, AZA/6-MP versus ASA;cP, 0.045, IFX versus ASA;dP, 0.048, AZA/6-MP + IFX versus ASA (b) Percentage of patients with EBER-1 positivity in mucosal in different groups.aP, 0.151, glucocorticoids versus ASA;bP, 0.014, AZA/6-MP versus AZA;cP, 0.083, IFX versus ASA.dP, 0.025 AZA/6-MP + IFX versus ASA

Figure 2: (a) Percentage of patients with EBV DNA in blood in different groups.<sup>a</sup><i>P</i>, 0.09, glucocorticoids versus ASA;<sup>b</sup><i>P</i>, 0.008, AZA/6-MP versus ASA;<sup>c</sup><i>P</i>, 0.045, IFX  versus  ASA;<sup>d</sup><i>P</i>, 0.048, AZA/6-MP + IFX versus ASA (b) Percentage of patients with EBER-1 positivity in mucosal in different groups.<sup>a</sup><i>P</i>, 0.151, glucocorticoids versus ASA;<sup>b</sup><i>P</i>, 0.014, AZA/6-MP versus AZA;<sup>c</sup><i>P</i>, 0.083, IFX versus ASA.<sup>d</sup><i>P</i>, 0.025 AZA/6-MP + IFX versus ASA